Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.24) by 50 percent. This is a 14.29 percent increase over losses of $(0.42) per share from the same period last year. The company reported quarterly sales of $49.32 million which missed the analyst consensus estimate of $81.70 million by 39.63 percent. This is a 6.80K percent increase over sales of $715.00 thousand the same period last year.